Discuss This Drug

eptifibatide

CHEBI:CHEBI_291902

Definition

A synthetic homodetic cyclic peptide comprising N(alpha)-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulfide bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/IIIa receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures.

Chemical Information

Molecular Formula
C35H49N11O9S2
Molecular Mass
831.96200
Charge
0
SMILES
[H][C@@]1(Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(N)=N)NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C1=O)C(N)=O
InChI
InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
InChIKey
CZKPOZZJODAYPZ-LROMGURASA-N

Alternative Names

  • [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
  • EPTIFIBATIDE
  • N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide
  • S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:291902
DRON_00010000
75635
oboInOwl#hasDbXref
Wikipedia:Eptifibatide

Additional References

Wikipedia:Eptifibatide

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:291902
active_ingredient_name
EPTIFIBATIDE
nui
N0000008832
pharm_class_epc
Platelet Aggregation Inhibitor [EPC]
pharm_class
Decreased Platelet Aggregation [PE]
pharm_class_pe
Decreased Platelet Aggregation [PE]
active_ingredient_strength
75 mg/100mL
upc
0352958402017
spl_set_id
3e7e7cd3-8efa-4d91-a5ab-7fd78b0cc65e
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rxcui
1736477
listing_expiration_date
20251231
package_marketing_start_date
09-OCT-12
route
INTRAVENOUS
manufacturer_name
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
spl_id
ee33453c-6399-e547-e053-2a95a90aeb82
package_ndc
70436-027-80
package_description
100 mL in 1 VIAL (70436-027-80)
unii
NA8320J834
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
75635
oboInOwl#hasDbXref
Wikipedia:Eptifibatide
oboInOwl#id
CHEBI:291902
generic_name
Eptifibatide
brand_name
Eptifibatide
brand_name_base
Eptifibatide
product_type
BULK INGREDIENT
marketing_category
BULK INGREDIENT
dosage_form
INJECTION, SOLUTION
marketing_start_date
20161208
labeler_name
Hainan Shuangcheng Pharmaceuticals Co., Ltd
product_ndc
70436-027
application_number
ANDA209864
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_50427
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect14974
owl#annotatedSource
t169521
owl#someValuesFrom
t2988553